WO1991016065A1 - Hepatic disorder inhibitor - Google Patents
Hepatic disorder inhibitor Download PDFInfo
- Publication number
- WO1991016065A1 WO1991016065A1 PCT/JP1991/000569 JP9100569W WO9116065A1 WO 1991016065 A1 WO1991016065 A1 WO 1991016065A1 JP 9100569 W JP9100569 W JP 9100569W WO 9116065 A1 WO9116065 A1 WO 9116065A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glutathione
- compound
- methyl
- inhibitor according
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a liver damage inhibitor comprising a novel and useful S-lower fatty acid glutathione derivative.
- S- (2-carboxypropyl) glucanthione is a powerful protein isolated from onion and garlic (Virtanen and Matikkala, 1960; Suzuki et al, 1961), and little is known about its pharmacological effects. It is not currently done.
- a glutathione derivative has a platelet aggregation inhibitory action, an anti-inflammatory action, an anti-allergic action, an antitumor action, and a liver damage inhibitory action
- Japanese Patent Application Laid-open No. Sho 63-83 337 Japanese Patent Application No. 1-799556, Japanese Patent Application No. 1--1 8 3 4 8 4, Japanese Patent Application No. 1--2 5 1 5 3 4 — 2 5 6 3 7 0, Japanese Patent Application 2—3 6 7 4 5).
- the present inventors have synthesized various novel glutathione derivatives in search of compounds having even more excellent medicinal effects, and have intensively searched for their medicinal effects together with the above-mentioned S- (2-carboquinpropyl) glutathione.
- S- (2-carboxypropyl) daltathione, and also glutathione or its esters, acrylic acid, methacrylic acid, crotonic acid, and gay cinnamate.
- Reacts with (or yS) halogenated organic monocarboxylic acids such as monochloroacetic acid or their esters or amides.
- the inventors have found that the obtained compound or a salt thereof has an excellent liver injury-suppressing effect, and have completed the present invention based on this new finding.
- R and R 3 in the formula are lower alkyl groups, those having 1 to 10 carbon atoms are preferred.
- the alkyl group may be linear, branched or cyclic, or may contain a cyclic moiety.
- R 2 represents hydrogen, a lower alkyl group or a phenyl group.
- the lower alkyl group has the same meaning as described above, and the phenyl group may be substituted with an alkyl group or the like.
- ⁇ represents a hydroxyl group, a lower alkoxy group or an amino group.
- Lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, ⁇ -pentyloxy, and isopentyloxy.
- the lower alkoxy group may contain a cyclic moiety such as a hydroxyl group or a funyl group. Further, hydrogen on the amino group may be substituted with an alkyl group or the like.
- the compound is a free acid or a pharmacologically non-toxic salt, for example, an alkali metal salt such as a sodium salt or a potassium salt, or an alkaline earth metal such as a calcium salt or a magnesium salt. It can be used as a salt.
- alkali metal salt such as a sodium salt or a potassium salt
- alkaline earth metal such as a calcium salt or a magnesium salt.
- These salts may be those in which all of the carboquine groups present in the present compound form a salt, or those in which a part thereof is in a salt form. Any of these can be used as appropriate for the preparation of the present formulation.
- This formulation effectively suppresses the occurrence of acute and chronic liver damage and suppresses the rise of G0T and GPT levels, and is useful for the prevention and treatment of acute or chronic hepatitis, and also for the prevention and treatment of cirrhosis It can be used for For example, it can be advantageously used for liver damage caused by drugs such as acetoaminophen.
- the preparation of the present invention is suitably used orally or parenterally as a liver damage inhibitor.
- the form of the preparation may be, for example, a tablet, a granule, a solid preparation such as a powder or capsule, or a liquid preparation such as an injection, which is appropriately prepared by a known method according to the type of disease. Can be.
- These preparations usually contain binders, disintegrants, thickeners, dispersants, resorption accelerators, flavoring agents, buffers, surfactants, solubilizing agents, preservatives, emulsifiers, isotonic agents, Excipients such as stabilizers and pH adjusters may be used as appropriate.
- the dosage of this active ingredient varies depending on the type of the compound, the type of the disease, the age and weight of the patient, the dosage form and the indications.For example, in the case of an injection, an adult once a day 1 to 500 In the case of oral administration, it is advisable to administer an adult several times a day, about 10 to 200 mg per dose.
- the drug of the present invention may contain one or more of the present active ingredients in an appropriate combination, if necessary.
- the drug of the present invention may appropriately contain other components exhibiting the same or different kinds of pharmacological effects as long as the object of the present invention is not adversely affected.
- the compounds of the present invention can be chemically synthesized as follows.
- glutathione, or glutathione monoester obtained by reacting glutathione with an alcohol corresponding to the target ester derivative in the presence of an acid such as sulfuric acid, is dissolved in an aqueous solution or an aqueous solution.
- an acid such as sulfuric acid
- ⁇ (or ⁇ ) halogenated organic monocarboxylic acids such as unsaturated fatty acids or monochloroacetic acid or their esters, such as acrylic acid, methacrylic acid, crotonic acid, gay cinnamate, etc.
- amide preferably at about pH 4 to 8 at room temperature or with stirring. The reaction is easily terminated.
- the target compound can be obtained by isolating and purifying this reaction solution by column chromatography or a recrystallization solvent. Most of the compounds where is hydrogen can also be purified via copper salts.
- the pH is again adjusted to 6.5 with 2N-sodium hydroxide.
- 2 ⁇ acetic acid and water were added to this to make a total volume of 200 mi, and 4.4 g of copper acetate was added thereto to dissolve and precipitate copper salts.
- the precipitate was collected by filtration, washed with water and methyl alcohol, suspended in water 20 and filtered while filtering with hydrogen sulfide as copper sulfide under stirring, and the filtrate was concentrated and precipitated.
- the dark white crystals are filtered and recrystallized from water, mp 194-195. 5.2 g of white crystals of (decomposition) are obtained.
- the animals used were SD male rats (weighing about 180 g) purchased from the Shizuoka Experimental Animal Agriculture Cooperative. One hour after the test substance was orally administered (0.5 mmole / kg), acetaminophen 300 mg / kg was intraperitoneally administered. Twenty-four hours later, blood was collected from the rat abdominal aorta to obtain serum. Then, s — GOT and GPT were measured.
- the unit is IU / ⁇ value iean person S.E.
- the number of cases is 7 to 10, () Internal occupation I ⁇ .
- One tablet is prepared by the usual method. Sugar-coated as needed.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91908176A EP0480061B1 (en) | 1990-04-26 | 1991-04-25 | Hepatic disorder inhibitor |
KR1019910701526A KR970008108B1 (ko) | 1990-04-26 | 1991-04-25 | 간 장해 억제제 |
DE69123428T DE69123428T2 (de) | 1990-04-26 | 1991-04-25 | Inhibitor von lebererkrankungen |
SU915011087A RU2019993C1 (ru) | 1990-04-26 | 1991-12-25 | Антигепатопатическая композиция |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11226090 | 1990-04-26 | ||
JP2/112260 | 1990-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991016065A1 true WO1991016065A1 (en) | 1991-10-31 |
Family
ID=14582257
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1991/000569 WO1991016065A1 (en) | 1990-04-26 | 1991-04-25 | Hepatic disorder inhibitor |
PCT/JP1991/000570 WO1991016337A1 (en) | 1990-04-26 | 1991-04-25 | S-(lower fatty acid)-substituted glutathione derivative |
PCT/JP1991/000581 WO1991016338A1 (en) | 1990-04-26 | 1991-04-26 | S-(lower fatty acid)-substituted glutathione derivative |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1991/000570 WO1991016337A1 (en) | 1990-04-26 | 1991-04-25 | S-(lower fatty acid)-substituted glutathione derivative |
PCT/JP1991/000581 WO1991016338A1 (en) | 1990-04-26 | 1991-04-26 | S-(lower fatty acid)-substituted glutathione derivative |
Country Status (10)
Country | Link |
---|---|
US (2) | US5232913A (ja) |
EP (3) | EP0480060B1 (ja) |
KR (3) | KR970002904B1 (ja) |
AT (3) | ATE145919T1 (ja) |
CA (2) | CA2060209A1 (ja) |
DE (3) | DE69123428T2 (ja) |
ES (3) | ES2095317T3 (ja) |
RU (1) | RU2046798C1 (ja) |
TW (1) | TW203060B (ja) |
WO (3) | WO1991016065A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6030950A (en) * | 1987-07-09 | 2000-02-29 | Ohlenschlaeger; Gerhard | Pharmaceutical therapeutic use of glutathione derivative |
US5599903A (en) * | 1992-04-03 | 1997-02-04 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
US5679643A (en) * | 1987-10-13 | 1997-10-21 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
KR970001509B1 (ko) * | 1990-02-17 | 1997-02-11 | 센쥬세이야꾸 가부시끼가이샤 | 글루타티온 유도체 |
US5786336A (en) * | 1991-04-29 | 1998-07-28 | Terrapin Technologies, Inc. | Target-selective protocols based on mimics |
US5955432A (en) * | 1992-04-03 | 1999-09-21 | Terrapin Technologies, Inc. | Metabolic effects of certain glutathione analogs |
TW225992B (ja) * | 1992-07-17 | 1994-07-01 | Senju Pharma Co | |
US5427425A (en) * | 1994-08-05 | 1995-06-27 | Droesch; Joaquin C. | Pickup tailgate mounting assembly |
ES2147162B1 (es) | 1999-01-27 | 2001-03-16 | Lacer Sa | "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias". |
US6596870B2 (en) | 2000-07-13 | 2003-07-22 | Brandeis University | Asymmetric synthetic methods based on phase transfer catalysis |
US7172905B2 (en) * | 2001-08-07 | 2007-02-06 | The University Of Chicago | Polypeptide immobilization |
WO2004005918A2 (en) * | 2002-07-05 | 2004-01-15 | University Of Chicago | Characterization of biochips containing self-assembled monolayers with maldi-tof-ms |
US20100021398A1 (en) * | 2008-01-18 | 2010-01-28 | Skinner Keith K | Compositions and methods for lightening skin and protecting skin from ultraviolet radiation with glutathione |
EP2295137B1 (en) * | 2008-05-28 | 2012-06-06 | Nagoya City University | Process for producing colloidal crystal |
JP5267096B2 (ja) * | 2008-12-12 | 2013-08-21 | 住友化学株式会社 | N,S−ジ−tert−ブトキシカルボニルグルタチオン蛍光誘導体及びそれを中間体として用いるグルタチオン蛍光誘導体の製造方法 |
US20130209366A1 (en) * | 2010-08-24 | 2013-08-15 | Oklahoma Medical Research Foundation | Glutathione-Lanthionine Compounds and Methods Related Thereto |
US9676818B2 (en) | 2013-01-17 | 2017-06-13 | University Of Kansas | Toll-like receptor 2-agonistic lipopeptides, and method of making the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60104018A (ja) * | 1983-11-11 | 1985-06-08 | Kyowa Hakko Kogyo Co Ltd | Ν−メチルホルムアミド肝毒性の軽減剤 |
JPS61249997A (ja) * | 1985-04-22 | 1986-11-07 | コ−ネル・リサ−チ・フアウンデ−シヨン・インコ−ポレイテツド | グルタチオンアルキルエステルおよびその用途 |
JPS6463525A (en) * | 1987-05-08 | 1989-03-09 | Yamanouchi Pharma Co Ltd | Alcoholic liver triglyceride increase-suppressing agent |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4879370A (en) * | 1983-12-02 | 1989-11-07 | Cornell Research Foundation, Inc. | Glutathione delivery system |
JPS60123497A (ja) * | 1983-12-02 | 1985-07-02 | コ−ネル・リサ−チ・フアウンデ−シヨン,インコ−ポレイテツド | グルタチオン伝達系 |
JPS60237963A (ja) * | 1984-05-02 | 1985-11-26 | Ajinomoto Co Inc | こく味調味料またはこく味の増強された食品の製造法 |
AU595193B2 (en) * | 1985-04-19 | 1990-03-29 | Smithkline Beckman Corporation | Thio substituted acidic derivatives |
JPS638337A (ja) * | 1986-06-30 | 1988-01-14 | Senjiyu Seiyaku Kk | 抗血液凝固剤 |
DE3784905T2 (de) * | 1986-07-07 | 1993-08-05 | Teijin Ltd | Gamma-l-glutamyl-l-cysteinethylester und arzneimittel, die dieses als aktives mittel enthalten. |
DE3722647A1 (de) * | 1987-07-09 | 1989-01-19 | Gerhard Ohlenschlaeger | Galenische verwendung eines tripeptids als arzneimittel |
JPH02255624A (ja) * | 1989-03-29 | 1990-10-16 | Senjiyu Seiyaku Kk | 血小板凝集抑制剤 |
US5102871A (en) * | 1989-04-24 | 1992-04-07 | Kyowa Hakko Kogyo Co., Ltd. | Nutrient composition |
JP2815179B2 (ja) * | 1989-07-14 | 1998-10-27 | 千寿製薬株式会社 | 抗炎症および/または抗アレルギー剤 |
US5093478A (en) * | 1989-07-14 | 1992-03-03 | Cornell Research Foundation, Inc. | Preparing glutathione monoesters |
JP2919867B2 (ja) * | 1989-09-27 | 1999-07-19 | 千寿製薬株式会社 | 抗腫瘍剤 |
JP2919870B2 (ja) * | 1989-09-29 | 1999-07-19 | 千寿製薬株式会社 | 肝障害抑制剤 |
KR970001509B1 (ko) * | 1990-02-17 | 1997-02-11 | 센쥬세이야꾸 가부시끼가이샤 | 글루타티온 유도체 |
-
1991
- 1991-04-25 RU SU915011089A patent/RU2046798C1/ru active
- 1991-04-25 DE DE69123428T patent/DE69123428T2/de not_active Expired - Fee Related
- 1991-04-25 EP EP91908175A patent/EP0480060B1/en not_active Expired - Lifetime
- 1991-04-25 CA CA002060209A patent/CA2060209A1/en not_active Abandoned
- 1991-04-25 DE DE69122831T patent/DE69122831T2/de not_active Expired - Fee Related
- 1991-04-25 ES ES91908176T patent/ES2095317T3/es not_active Expired - Lifetime
- 1991-04-25 WO PCT/JP1991/000569 patent/WO1991016065A1/ja active IP Right Grant
- 1991-04-25 EP EP91908176A patent/EP0480061B1/en not_active Expired - Lifetime
- 1991-04-25 US US07/778,134 patent/US5232913A/en not_active Expired - Fee Related
- 1991-04-25 AT AT91908176T patent/ATE145919T1/de not_active IP Right Cessation
- 1991-04-25 AT AT91908175T patent/ATE144531T1/de not_active IP Right Cessation
- 1991-04-25 KR KR1019910701527A patent/KR970002904B1/ko not_active IP Right Cessation
- 1991-04-25 WO PCT/JP1991/000570 patent/WO1991016337A1/ja active IP Right Grant
- 1991-04-25 KR KR1019910701526A patent/KR970008108B1/ko not_active IP Right Cessation
- 1991-04-25 ES ES91908175T patent/ES2093098T3/es not_active Expired - Lifetime
- 1991-04-26 ES ES91908790T patent/ES2092565T3/es not_active Expired - Lifetime
- 1991-04-26 KR KR1019910701528A patent/KR970002905B1/ko not_active IP Right Cessation
- 1991-04-26 EP EP91908790A patent/EP0480071B1/en not_active Expired - Lifetime
- 1991-04-26 WO PCT/JP1991/000581 patent/WO1991016338A1/ja active IP Right Grant
- 1991-04-26 US US07/773,595 patent/US5274177A/en not_active Expired - Fee Related
- 1991-04-26 CA CA002060210A patent/CA2060210A1/en not_active Abandoned
- 1991-04-26 AT AT91908790T patent/ATE143670T1/de not_active IP Right Cessation
- 1991-04-26 DE DE69122466T patent/DE69122466T2/de not_active Expired - Fee Related
- 1991-05-01 TW TW080103419A patent/TW203060B/zh active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60104018A (ja) * | 1983-11-11 | 1985-06-08 | Kyowa Hakko Kogyo Co Ltd | Ν−メチルホルムアミド肝毒性の軽減剤 |
JPS61249997A (ja) * | 1985-04-22 | 1986-11-07 | コ−ネル・リサ−チ・フアウンデ−シヨン・インコ−ポレイテツド | グルタチオンアルキルエステルおよびその用途 |
JPS6463525A (en) * | 1987-05-08 | 1989-03-09 | Yamanouchi Pharma Co Ltd | Alcoholic liver triglyceride increase-suppressing agent |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991016065A1 (en) | Hepatic disorder inhibitor | |
JPH02161A (ja) | アミノ酸から誘導される新規な光学異性体と、その製造方法と、その医薬への応用 | |
CA1101846A (en) | Derivatives of 4-hydroxy-phenylglycine | |
FR2501199A1 (fr) | Nouveaux polypeptides, leur preparation et leur application comme medicaments | |
JPH0541626B2 (ja) | ||
KR970001509B1 (ko) | 글루타티온 유도체 | |
US4228183A (en) | Novel phenethylamine derivatives and processes for preparing same | |
JPH03112933A (ja) | 抗腫瘍剤 | |
US5747521A (en) | N-cinnamoyl-2-methyl-5-methoxy-3-indoleacetic acid ester, and pharmaceutical preparation containing the same | |
JP2919870B2 (ja) | 肝障害抑制剤 | |
WO1990013557A1 (en) | New s-adenosylmethionine derivative | |
EP0588797A1 (en) | N - ((4,5-Dihydroxy- and 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracen-yl) carbonyl) amino acid for the treatment of osteoarticular disorders. | |
JP3029867B2 (ja) | S―低級脂肪酸グルタチオン誘導体 | |
RU2019993C1 (ru) | Антигепатопатическая композиция | |
JP2978562B2 (ja) | S―低級脂肪酸グルタチオン誘導体 | |
JPS63502432A (ja) | アシル化シアナミド組成物 | |
US4923888A (en) | Butenoic acid amides, their salts, and pharmaceutical compositions containing them | |
CA2060200A1 (en) | Antihepatopathic composition | |
JPS61277650A (ja) | 7−オキソ−pgi2エフエドリン塩類似体,その製造方法および医薬組成物 | |
CA1105053A (fr) | Sulfamido acetyleniques de benzamides utilisables en therapeutique | |
JP2717317B2 (ja) | N―アシルーチアゾリジン―2―チオン誘導体 | |
WO2001064661A1 (fr) | Antioxydants | |
WO1988009785A1 (en) | Butenoic acid amides, their salts, pharmaceutical compositions containing them and process for preparing same | |
US4940816A (en) | Acylated cyanamide compounds | |
JP2001316262A (ja) | 抗酸化剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP KR SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2060200 Country of ref document: CA Ref document number: 1991908176 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991908176 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991908176 Country of ref document: EP |